查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1884055

人類抗凝血酶市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032）

Human Antithrombin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 100 Pages | 商品交期: 請詢問到貨日

價格

人類抗凝血酶市場成長驅動因子

由於臨床意識的提高、罕見凝血障礙盛行率的增加以及在外科手術和重症監護領域應用範圍的擴大，全球人類抗凝血酶市場正經歷穩步增長。根據最新的產業分析，預計該市場在2024年的價值將達到3.671億美元，到2025年將達到3.813億美元。預計2032年將進一步成長至5.12億美元，預測期內複合年增長率（CAGR）為4.3%。 2024年，歐洲以43.28%的市佔率佔主導地位。這主要歸功於歐洲成熟企業的強大實力、完善的醫療保健基礎設施以及血漿來源抗凝血酶產品的廣泛供應。

人類抗凝血酶是一種源自人類血漿的糖蛋白，在滅活凝血酶和其他絲氨酸蛋白酶以及預防異常血液凝固方面發揮關鍵作用。抗凝血酶濃縮物在外科手術、心臟手術、器官移植和體外膜氧合（ECMO）治療的應用日益廣泛，推動了市場成長。此外，遺傳性抗凝血酶缺乏症、瀰漫性血管內凝血（DIC）和血栓形成的日益普遍，也進一步推動了全球對抗凝血酶替代療法的需求。

主要市場參與者包括 CSL、Octapharma AG、Grifols S.A.、Kedrion S.p.A. 和武田藥品工業株式會社。所有這些公司都受益於其強大的區域影響力以及在血漿分離產品領域成熟的產品組合。這些公司持續的創新和策略擴張將繼續支持市場成長。

市場驅動因素與機會

人類抗凝血酶市場的主要驅動因素是其在治療應用上日益廣泛的應用。遺傳性抗凝血酶缺乏症影響全球約 0.02% 至 0.05% 的人口，這意味著成千上萬的患者需要終身接受替代治療。抗凝血酶濃縮物在心臟手術患者的管理中尤其重要。例如，2024 年 6 月 "胸腔外科年鑑" 簡報報導，美國每年平均每 10 萬人口進行 271.5 例心臟手術，凸顯了臨床對抗凝血酶治療的依賴性。

此外，與肝素合併治療可產生協同抗凝血效果，為市場成長帶來新的潛力。此類聯合療法正越來越多地被納入臨床方案，以改善肝素抗性和複雜凝血障礙患者的治療效果。

市場限制因素與挑戰

儘管具有重要的臨床意義，但由於血漿來源抗凝血酶的安全性問題，包括過敏反應、出血風險以及潛在的感染風險，市場仍面臨許多限制。高劑量，尤其是在嚴重敗血症或與肝素合併使用時，會增加出血風險，從而限制了其在某些患者群體中的應用。

此外，複雜的監管框架和不一致的報銷政策，尤其是在中低收入國家，也構成了市場挑戰。冗長的審批流程、嚴格的安全法規以及有限的保險覆蓋範圍延緩了新產品的廣泛應用和商業化。

市場趨勢

近期趨勢表明，抗凝血酶製劑的應用範圍正在擴大，不再局限於遺傳性凝血功能障礙。在日本，抗凝血酶已被納入膿毒症合併彌散性血管內凝血（DIC）患者的標準治療方案，獲批劑量高達每日1500國際單位（IU），這充分體現了此類產品的治療多樣性。此外，外科手術中對抗凝劑的臨床需求持續推動終端使用者（主要是醫院和診所）的採用。同時，製藥和生技產業也在拓展其在研究和診斷領域的應用。

區隔市場分析

  • 依應用領域劃分：截至2024年，由於其在外科手術和肝素抗性患者中的廣泛應用，治療性應用佔了最大的市場佔有率。研究和診斷性應用也在成長，但成長較慢。
  • 依劑型劃分：冷凍乾燥粉末因其穩定性佳、易於操作而佔主導地位，廣泛應用於Thrombotrol VF（CSL）和THROMBATE III（Grifors）等產品。液體製劑的市佔率微乎其微。
  • 依最終使用者劃分：醫院和診所是最大的最終使用者群體，因為在治療過程中需要直接使用抗凝血酶。

依地區劃分的預測

  • 歐洲：是最大的地區，預計2024年市場規模將達到1.589億美元。這得歸功於強大的血漿分離中心網絡以及法國2030等政府舉措，這些舉措旨在促進國內生物製藥生產。
  • 亞太地區：由於人們對先天性抗凝血酶缺乏症的認識不斷提高以及血漿生產基礎設施的不斷完善，亞太地區是成長最快的地區。
  • 北美：對血漿衍生產品的嚴格監管限制了其市場佔有率。
  • 世界其他地區：包括拉丁美洲、中東和非洲。產品普及率低和基礎設施限制導致其普及速度較慢。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家主要心血管疾病盛行率
  • 主要國家監管狀況
  • 主要產業趨勢（併購、合作、核准、上市等）

第五章：全球人類抗凝血酶市場分析、洞察與預測 （2019-2032）

  • 依應用領域劃分的市場分析、洞察與預測
    • 治療用途
    • 研究與診斷
  • 依劑型劃分的市場分析、洞察與預測
    • 凍乾粉
    • 液體
  • 依最終用戶劃分的市場分析、洞察和預測
    • 醫院和診所
    • 製藥和生物技術
    • 研究機構
  • 依地區劃分的市場分析、洞察與預測
    • 北美
    • 歐洲
    • 亞太地區
    • 世界其他地區

第六章：北美人抗凝血酶市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲人類抗凝血酶市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區人類抗凝血酶市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 南非韓國 東南亞 亞太其他地區

第九章：世界其他地區人類抗凝血酶市場分析、洞察與預測（2019-2032）

第十章：競爭分析

  • 全球市場佔有率分析(2024年)
  • 企業簡介
    • CSL
    • Octapharma AG
    • Takeda Pharmaceutical Company Limited
    • Grifols, S.A.
    • Medix Biochemica
    • Kedrion S.p.A.
    • Scripps Laboratories
Product Code: FBI113611

Growth Factors of human antithrombin Market

The global human antithrombin market is witnessing steady growth due to rising clinical awareness, increasing prevalence of rare coagulation disorders, and expanding applications in surgical and intensive care settings. According to the latest industry insights, the market was valued at USD 367.1 million in 2024, is projected to reach USD 381.3 million in 2025, and is expected to grow to USD 512.0 million by 2032, reflecting a CAGR of 4.3% during the forecast period. In 2024, Europe dominated the market with a 43.28% share, attributed to the strong presence of established players, well-developed healthcare infrastructure, and wide availability of plasma-derived antithrombin products.

Human antithrombin, a glycoprotein derived from human plasma, plays a crucial role in inactivating thrombin and other serine proteases, preventing abnormal blood clotting. The growing adoption of antithrombin concentrates in surgical procedures, cardiac surgeries, organ transplants, and Extracorporeal Membrane Oxygenation (ECMO) treatments drives market expansion. Additionally, increasing prevalence of hereditary antithrombin deficiency, disseminated intravascular coagulation (DIC), and thrombophilia further fuels global demand for antithrombin supplementation.

Major market players include CSL, Octapharma AG, Grifols S.A., Kedrion S.p.A., and Takeda Pharmaceutical Company Limited, all of which benefit from strong regional presence and established product portfolios in plasma fractionated products. Their ongoing innovations and strategic expansions continue to support the market growth.

Market Drivers and Opportunities

The primary driver of the human antithrombin market is increasing usage in therapeutic applications. Hereditary antithrombin deficiency affects roughly 0.02% to 0.05% of the global population, translating to thousands of patients requiring lifelong supplementation. Antithrombin concentrates are especially critical in managing patients undergoing cardiac surgeries. For instance, in June 2024, the Annals of Thoracic Surgery Short Reports highlighted that the annual average cardiac surgery volume in the U.S. was 271.5 per 100,000 population, emphasizing the clinical reliance on antithrombin therapies.

Moreover, combination therapies with heparin provide synergistic anticoagulant effects, presenting new avenues for market growth. Such therapies are increasingly incorporated in clinical protocols to enhance therapeutic outcomes in patients with heparin resistance or complex coagulopathies.

Market Restraints and Challenges

Despite its clinical importance, the market faces constraints due to plasma-derived antithrombin safety concerns, including allergic reactions, hemorrhage risk, and potential exposure to infectious agents. High doses, particularly during severe sepsis or when co-administered with heparin, may increase bleeding risks, limiting adoption in certain patient populations.

Additionally, the market is challenged by complex regulatory frameworks and inconsistent reimbursement scenarios, particularly in low- and middle-income countries. Lengthy approval processes, strict safety regulations, and limited insurance coverage hinder widespread adoption and slow commercialization of new products.

Market Trends

Recent trends indicate the expansion of antithrombin applications beyond hereditary deficiencies. In Japan, antithrombin is part of standard care for septic patients with DIC, with approved doses reaching 1,500 IU/day, demonstrating the therapeutic versatility of these products. Moreover, hospitals and clinics continue to lead end-user adoption due to the clinical demand for anticoagulants during surgical procedures, while pharmaceutical and biotechnology industries are increasing research and diagnostic applications.

Segmentation Analysis

  • By Application: The therapeutic segment held the largest market share in 2024 due to widespread use in surgeries and heparin-resistant patients. Research and diagnostic applications are growing but at a slower pace.
  • By Dosage Form: Lyophilized powders dominate owing to enhanced stability and ease of handling, used in products such as Thrombotrol VF (CSL) and THROMBATE III (Grifols). Liquid formulations account for minimal market share.
  • By End User: Hospitals and clinics represent the largest end-user segment due to the direct administration of antithrombin in therapeutic procedures.

Regional Outlook

  • Europe: Leading region with USD 158.9 million in 2024, supported by a strong network of plasma fractionation centers and government initiatives like France 2030, which promote local biologics production.
  • Asia Pacific: Fastest-growing region due to rising congenital antithrombin deficiency awareness and expanding plasma production infrastructure.
  • North America: Limited share due to stringent regulatory hurdles for plasma-derived products.
  • Rest of the World: Includes Latin America and Middle East & Africa, with slower adoption owing to limited product penetration and infrastructure constraints.

Competitive Landscape

The market is semi-consolidated, with CSL, Grifols S.A., Kedrion S.p.A., and Octapharma AG dominating. These companies leverage extensive product portfolios, manufacturing capabilities, and strategic collaborations to maintain leadership. Other global participants include Takeda Pharmaceutical Company Limited and Medix Biochemica, focusing on expanding antithrombin applications and research collaborations.

Conclusion

With a market value of USD 367.1 million in 2024, rising to USD 381.3 million in 2025, and projected to reach USD 512.0 million by 2032, the global human antithrombin market is poised for steady growth. Key drivers include therapeutic demand in surgeries, combination therapies, and rising awareness of coagulation disorders, while challenges such as safety concerns and regulatory barriers persist. Ongoing research, expansion in Asia Pacific, and innovative product launches are expected to shape the market trajectory through 2032.

Segmentation By Application

  • Therapeutic
  • Research & Diagnostic

By Dosage Form

  • Lyophilized Powder
  • Liquid

By End User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Industry
  • Research Institutes

By Region

  • North America (By Application, Dosage Form, End User, and Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Application, Dosage Form, End User, and Country/Sub-Region)
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Application, Dosage Form, End User, and Country/Sub-Region)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Application, Dosage Form, and End User)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Cardiovascolar Diseases, By Key Countries
  • 4.2. Regolatory Scenario, By Key Countries
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Approvals, Launches etc.)

5. Global Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Therapeutic
    • 5.1.2. Research & Diagnostic
  • 5.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.2.1. Lyophilized Powder
    • 5.2.2. Liquid
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Pharmaceutical & Biotechnology Industry
    • 5.3.3. Research Institutes
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Therapeutic
    • 6.1.2. Research & Diagnostic
  • 6.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.2.1. Lyophilized Powder
    • 6.2.2. Liquid
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Pharmaceutical & Biotechnology Industry
    • 6.3.3. Research Institutes
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Therapeutic
    • 7.1.2. Research & Diagnostic
  • 7.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.2.1. Lyophilized Powder
    • 7.2.2. Liquid
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Pharmaceutical & Biotechnology Industry
    • 7.3.3. Research Institutes
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. Germany
    • 7.4.2. UK
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Therapeutic
    • 8.1.2. Research & Diagnostic
  • 8.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.2.1. Lyophilized Powder
    • 8.2.2. Liquid
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Pharmaceutical & Biotechnology Industry
    • 8.3.3. Research Institutes
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. South Korea
    • 8.4.6. Southeast Asia
    • 8.4.7. Rest of Asia Pacific

9. Rest of World Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Therapeutic
    • 9.1.2. Research & Diagnostic
  • 9.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.2.1. Lyophilized Powder
    • 9.2.2. Liquid
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Pharmaceutical & Biotechnology Industry
    • 9.3.3. Research Institutes

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles
    • 10.2.1. CSL
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. Financials (Based on Availability)
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. SWOT,Etc.
    • 10.2.2. Octapharma AG
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. Financials (Based on Availability)
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. SWOT,Etc.
    • 10.2.3. Takeda Pharmaceutical Company Limited
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. Financials (Based on Availability)
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. SWOT,Etc.
    • 10.2.4. Grifols, S.A.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. Financials (Based on Availability)
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. SWOT,Etc.
    • 10.2.5. Medix Biochemica
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. Financials (Based on Availability)
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. SWOT,Etc.
    • 10.2.6. Kedrion S.p.A.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. Financials (Based on Availability)
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. SWOT,Etc.
    • 10.2.7. Scripps Laboratories
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. Financials (Based on Availability)
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. SWOT,Etc.

List of Tables

  • Table 1: Global Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 2: Global Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 3: Global Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 4: Global Human Antithrombin Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 5: North America Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 6: North America Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 7: North America Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 8: North America Human Antithrombin Market Revenue (USD million) Forecast, By Country, 2019-2032
  • Table 9: Europe Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 10: Europe Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 11: Europe Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 12: Europe Human Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 14: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 15: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 16: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 18: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 19: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2019-2032

List of Figures

  • Figure 1: Global Human Antithrombin Market Revenue Breakdown (USD million, %) by Region, 2024 & 2032
  • Figure 2: Global Human Antithrombin Market Value Share (%), by Application, 2024 & 2032
  • Figure 3: Global Human Antithrombin Market Value Share (%), by Dosage Form, 2024 & 2032
  • Figure 4: Global Human Antithrombin Market Value Share (%), by End User, 2024 & 2032
  • Figure 5: Global Human Antithrombin Market Value (USD million), by Region, 2024 & 2032
  • Figure 6: North America Human Antithrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 7: North America Human Antithrombin Market Value Share (%), by Application, 2024
  • Figure 8: North America Human Antithrombin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 9: North America Human Antithrombin Market Value Share (%), by Dosage Form, 2024
  • Figure 10: North America Human Antithrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 11: North America Human Antithrombin Market Value Share (%), by End User, 2024
  • Figure 12: North America Human Antithrombin Market Value (USD million), By Country, 2024 & 2032
  • Figure 13: North America Human Antithrombin Market Value Share (%), By Country, 2024
  • Figure 14: Europe Human Antithrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 15: Europe Human Antithrombin Market Value Share (%), by Application, 2024
  • Figure 16: Europe Human Antithrombin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 17: Europe Human Antithrombin Market Value Share (%), by Dosage Form, 2024
  • Figure 18: Europe Human Antithrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 20: Europe Human Antithrombin Market Value Share (%), by End User, 2024
  • Figure 21: Europe Human Antithrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 22: Europe Human Antithrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 23: Asia Pacific Human Antithrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 24: Asia Pacific Human Antithrombin Market Value Share (%), by Application, 2024
  • Figure 25: Asia Pacific Human Antithrombin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 26: Asia Pacific Human Antithrombin Market Value Share (%), by Dosage Form, 2024
  • Figure 27: Asia Pacific Human Antithrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 28: Asia Pacific Human Antithrombin Market Value Share (%), by End User, 2024
  • Figure 29: Asia Pacific Human Antithrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 30: Asia Pacific Human Antithrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 31: Rest of the World Human Antithrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 32: Rest of the World Human Antithrombin Market Value Share (%), by Application, 2024
  • Figure 33: Rest of the World Human Antithrombin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 34: Rest of the World Human Antithrombin Market Value Share (%), by Dosage Form, 2024
  • Figure 35: Rest of the World Human Antithrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 36: Rest of the World Human Antithrombin Market Value Share (%), by End User, 2024
  • Figure 37: Global Human Antithrombin Market Share (%), By Company, 2024